This page shows what was measured, who it was measured in, and what that does not settle.
What Secukinumab does in the body
Psoriasis, psoriatic arthritis and inflammatory spine disease
Interleukin-17A is the final instruction that tells skin cells to divide too fast and calls in the white cells that make a psoriasis plaque scaly. Secukinumab is an antibody that mops that instruction out of the tissue. Because it acts at the last step rather than upstream, skin clears fast, often within four to eight weeks.
What happened in people
PASI 75 at week 12 in 81.6% (ERASURE 300 mg) and 77.1% (FIXTURE 300 mg) versus 4.5% and 4.9% on placebo
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The recorded finding that sits closest to something a person would notice. Written into the record, not signed off, and it carries no population or interval.
ClinicalTrials.gov, ERASURE (NCT01365455) · a recorded source, not a stored snapshot
The limit that matters most
That an inflammatory cytokine is pathogenic wherever it appears; IL-17A is protective in the intestinal barrier
Where it acts
Skin epidermis, entheses and axial synovium
Kind of result
The kind of result is not recorded
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as protein.
FDA substance registry · DLG4EML025 · read 2026-08-29
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
A limit recorded against this substance. Not signed off as a reviewed claim.
The four opening statements run to 90 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Body weight
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved1 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Body weight
body weight
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
△ Only a number moved
1 registered test measure.
— Not recorded
Harms were not a registered measure for this goal.
… Waiting for a reviewer
Who was studied is listed further down the page.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Results from the one trial this record names
In NCT01365455, PASI 75 response: the proportion of subjects achieving a reduction of at least 75% in the Psoriasis Area and Severity Index from baseline, one of the two trial endpoints in Trial PsO1 was Secukinumab 300 mg (N = 245): 200 subjects (82%) against Placebo (N = 248): 11 subjects (4%) in the comparison group at Week 12.
US prescribing information · 77c4b13e-7df3-42d4-81db-3d0cddb7f67a · read 2026-08-28
In NCT01365455, Treatment success on the Investigator’s Global Assessment modified 2011, recorded as clear or almost clear, the other trial endpoint in Trial PsO1 was Secukinumab 300 mg (N = 245): 160 subjects (65%) against Placebo (N = 248): 6 subjects (2%) in the comparison group at Week 12.
US prescribing information · 77c4b13e-7df3-42d4-81db-3d0cddb7f67a · read 2026-08-28
Co-primary PASI 75 and modified IGA 0 or 1 at week 12
✓ The study showed what it set out to show
Who was studied
ERASURE (NCT01365455)
How many people
738
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
p < 0.001 for both secukinumab doses versus placebo
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous prefilled syringe, autoinjector pen or 30-minute intravenous infusion for some indications
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
ClinicalTrials.gov, ERASURE (NCT01365455) · a recorded source, not a stored snapshot
Drugs@FDA, COSENTYX BLA 125504, original approval 21 January 2015 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=12… · a recorded source, not a stored snapshot
Co-primary PASI 75 and modified IGA 0 or 1 at week 12, with an active etanercept comparator arm
✓ The study showed what it set out to show
Who was studied
FIXTURE (NCT01358578)
How many people
1306
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
p < 0.001 versus placebo and versus etanercept
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous prefilled syringe, autoinjector pen or 30-minute intravenous infusion for some indications
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
ClinicalTrials.gov, ERASURE (NCT01365455) · a recorded source, not a stored snapshot
Drugs@FDA, COSENTYX BLA 125504, original approval 21 January 2015 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=12… · a recorded source, not a stored snapshot
Bayesian probability that secukinumab reduces CDAI by at least 50 points more than placebo at week 6
ClinicalTrials.gov, ERASURE (NCT01365455) · a recorded source, not a stored snapshot
Drugs@FDA, COSENTYX BLA 125504, original approval 21 January 2015 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=12… · a recorded source, not a stored snapshot
What we know
RNAWiki holds 3 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.4 registered measures of this kind. No reviewed result.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.2 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.1 registered measure inside human tissue.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Rat. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it changes in the body◇Read from sources, not yet reviewed
The path through the body
From what a person takes to what changes. A solid line is a step measured in people. A dashed line is a step nobody has measured that way.
Where a source records it acting
Immune and lymphatic system: Selectively binds to the interleukin-17A cytokine, which is involved in normal inflammatory and immune responses, and inhibits its interaction with the IL-17 receptor and the release of proinflammatory cytokines and chemokines
US prescribing information · 77c4b13e-7df3-42d4-81db-3d0cddb7f67a · read 2026-08-28
Skin: Elevated interleukin-17A levels are found in psoriatic plaques and hidradenitis suppurativa lesions; the label records that treatment may reduce epidermal neutrophils and interleukin-17A levels in psoriatic plaques
US prescribing information · 77c4b13e-7df3-42d4-81db-3d0cddb7f67a · read 2026-08-28
Start
Secukinumab
What a person takes: Subcutaneous prefilled syringe, autoinjector pen or 30-minute intravenous infusion for some indications.
The measurement behind this step
300 mg subcutaneously weekly for five weeks then every four weeks in psoriasis, with lower doses in some rheumatological indications and an intravenous loading option approved in 2023.
Getting in
Weekly loading then monthly subcutaneous injection
Five weekly injections load the system, then one injection a month keeps it going. Most people inject themselves at home.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
300 mg subcutaneously at weeks 0, 1, 2, 3 and 4 then every 4 weeks in psoriasis, with a terminal half-life of roughly 27 days and bioavailability near 55-77%.
ClinicalTrials.gov, ERASURE (NCT01365455) · a recorded source, not a stored snapshot
Reaching the cell
Accumulation in dermis and entheses
It reaches the skin and the points where tendons attach to bone, the two places where this cytokine does most of its damage.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Distributes into the interstitium of psoriatic dermis and into entheseal tissue where IL-17-producing gamma-delta T cells and innate lymphoid cells reside; volume of distribution is small at around 7-8 L.
ClinicalTrials.gov, ERASURE (NCT01365455) · a recorded source, not a stored snapshot
What it acts on
Neutralising IL-17A in the tissue
The antibody binds the messenger itself, in the fluid between cells, before it can reach the skin cells it was addressed to.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Binds IL-17A homodimer and the IL-17A/F heterodimer, preventing engagement of the IL-17RA and IL-17RC receptor complex. It does not neutralise IL-17F homodimer, which is the difference bimekizumab was built to close.
ClinicalTrials.gov, ERASURE (NCT01365455) · a recorded source, not a stored snapshot
The change it makes
Keratinocyte signalling and neutrophil recruitment collapse
Skin cells stop being told to divide fast, and the chemical signals that draw white cells into the plaque are no longer produced.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Without IL-17RA and IL-17RC engagement, Act1-mediated NF-kB and C/EBP signalling in keratinocytes falls, cutting CXCL1, CXCL8, beta-defensin, S100A7 and lipocalin-2 output. Neutrophil influx and Munro microabscess formation resolve.
ClinicalTrials.gov, ERASURE (NCT01365455) · a recorded source, not a stored snapshot
What that does for a person
Rapid skin clearance and control of enthesitis
Plaques flatten and disappear over four to twelve weeks, faster than with drugs acting further upstream. Tendon attachment pain and joint swelling also improve.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Normalisation of epidermal turnover and resolution of parakeratosis, with reduced entheseal inflammation on MRI and reduced radiographic progression in psoriatic arthritis extension studies.
ClinicalTrials.gov, ERASURE (NCT01365455) · a recorded source, not a stored snapshot
No suggested links are held for this record, so nothing is hidden from this path.
What we know
The record describes 5 steps from taking it to an effect in a person.
How we know it
Each step names the study behind it in the technical detail beside it.
What this does not prove
A change inside the body is a reason to look. It is not a result in a person.
Why it matters
A reader can see exactly where the chain stops being measured in people.
What we still do not know
No reviewed claim binds any of these steps to a named population.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Things that change how a life goes, not only a number.
adverse events serious adverse events and deaths
hospitalized infection or death
time to relapse
sustained remission
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (33)
total neutrophil cell count in 106/ in induced sputum
adverse events
rate of recurrence
reported adverse events
adverse events and serious adverse events
adverse events as a measure of safety and tolerability
achieving an american college of rheumatology response 20
polymyalgia rheumatica activity
adverse events as a measure of safety
american college of rheumatology 20 response
auc0 12
auclast
aucinf
physician s global assessment
incidence of treatment emergent adverse events
iga mod 2011 0 or 1 at week 12
papule/pustule count at week 16
hidradenitis suppurativa clinical response
no radiographic progression at week 104
a pasi 90 at week 52
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 22 to 31 days
Read from the label, which states: “The mean systemic clearance (CL) ranged from 0.14 L/day to 0.22 L/day and the mean half-life ranged from 22 to 31 days in PsO subjects following intravenous and subcutaneous administration across all PsO trials.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Adults and children with moderate-to-severe plaque psoriasis, and adults with psoriatic arthritis or axial spondyloarthritis, typically after topical therapy, phototherapy or a conventional systemic agent has failed.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
Who a named study recorded including and excluding
NCT01365455 recorded its participants as: Adults 18 years and older, all sexes eligible.
ClinicalTrials.gov record · NCT01365455 · read 2026-08-28
It included: Moderate and severe plaque-type psoriasis diagnosed for at least 6 months; Psoriasis Area and Severity Index (PASI) score of 12 or greater; Investigator's Global Assessment (IGA) score of 3 or greater; Total body surface area (BSA) affected of 10% or greater; Inadequate control by prior use of topical treatment, phototherapy and/or systemic therapy.
ClinicalTrials.gov record · NCT01365455 · read 2026-08-28
It excluded: Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate); Current drug-induced psoriasis; Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor; Significant medical problems such as uncontrolled hypertension, congestive heart failure or a condition that significantly immunocompromises the subject; History of an ongoing, chronic or recurrent infectious disease, or evidence of untreated tuberculosis; History of lymphoproliferative disease or history of malignancy of any organ system within the past 5 years.
ClinicalTrials.gov record · NCT01365455 · read 2026-08-28
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of COSENTYX in pediatric patients with PsO below the age of 6 years old have not been established.”
US prescribing information · 77c4b13e-7df3-42d4-81db-3d0cddb7f67a · read 2026-08-30
On older people, the label states: “Clinical trials in HS did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger adult subjects.”
US prescribing information · 77c4b13e-7df3-42d4-81db-3d0cddb7f67a · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Limited available human data with COSENTYX use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes.”
US prescribing information · 77c4b13e-7df3-42d4-81db-3d0cddb7f67a · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary It is not known whether secukinumab is excreted in human milk or absorbed systemically after ingestion.”
US prescribing information · 77c4b13e-7df3-42d4-81db-3d0cddb7f67a · read 2026-08-30
Where the result stopped carrying
The Crohn disease proof-of-concept trial not only missed its endpoint but was associated with more withdrawals for lack of effect and more infections than placebo
IL-17F homodimer is not neutralised by secukinumab, a gap that motivated the development of dual IL-17A/F blockade
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Given by a clinician
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Subcutaneous prefilled syringe, autoinjector pen or 30-minute intravenous infusion for some indications
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1.
No source is stored against this line.
What is in the pack
300 mg subcutaneously weekly for five weeks then every four weeks in psoriasis, with lower doses in some rheumatological indications and an intravenous loading option approved in 2023.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
The recorded stepping schedule
What follows is the schedule printed on the label, recorded as it is written there. It is a record of what was done, not a recommendation.
US prescribing information · 77c4b13e-7df3-42d4-81db-3d0cddb7f67a · read 2026-08-28
Weeks 0, 1, 2, 3, and 4 (adult plaque psoriasis, subcutaneous): 300 mg by subcutaneous injection
US prescribing information · 77c4b13e-7df3-42d4-81db-3d0cddb7f67a · read 2026-08-28
Every 4 weeks thereafter: 300 mg by subcutaneous injection; the label records that for some patients a dose of 150 mg may be acceptable
US prescribing information · 77c4b13e-7df3-42d4-81db-3d0cddb7f67a · read 2026-08-28
What it would be like to take◇Read from sources, not yet reviewed
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
·Worth asking a clinician aboutWritten into the record from the studies named on this page
No boxed warning. Mucocutaneous candidiasis, upper respiratory infection and neutropenia are the characteristic events. Exacerbation or new onset of inflammatory bowel disease is a specific warning, and the drug should not be used in patients with active Crohn disease or ulcerative colitis.
Nobody counted how many people took this and were fine, so this cannot be turned into a rate.
ClinicalTrials.gov, ERASURE (NCT01365455) · a recorded source, not a stored snapshot
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Secukinumab appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 16345 reaction mentions were counted. One report can name several reactions.
The recorded terms (10)
psoriasis — 3770 reaction mentions
pain — 2393 reaction mentions
arthralgia — 2101 reaction mentions
psoriatic arthropathy — 1516 reaction mentions
malaise — 1487 reaction mentions
pruritus — 1411 reaction mentions
pain in extremity — 1171 reaction mentions
nasopharyngitis — 997 reaction mentions
musculoskeletal stiffness — 765 reaction mentions
joint swelling — 734 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Subcutaneous prefilled syringe, autoinjector pen or 30-minute intravenous infusion for some indications
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
6 products list this as an active ingredient in the United States drug directory. 6 of them contain it and nothing else.
FDA National Drug Code directory · 0078-1070 · read 2026-08-29
They are sold as injection, injection, solution, concentrate and liquid, taken intravenous and subcutaneous.
FDA National Drug Code directory · 0078-1070 · read 2026-08-29
The regulator's established pharmacologic class for it is interleukin-17a antagonist [epc] and interleukin-17a antagonists [moa].
FDA National Drug Code directory · 0078-1070 · read 2026-08-29
1 published label names it as an active ingredient. 1 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 77c4b13e-7df3-42d4-81db-3d0cddb7f67a · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 77c4b13e-7df3-42d4-81db-3d0cddb7f67a · read 2026-08-29
Cosentyx is injection for subcutaneous use (single-dose unoready pen, sensoready pen and prefilled syringe) and injection for intravenous use (single-dose vial) at Subcutaneous: 300 mg/2 mL, 150 mg/mL, 75 mg/0.5 mL. Intravenous: 125 mg/5 mL, recorded as prescription biologic product; fda label in effect 2026-04-17 in the United States.
US prescribing information · 77c4b13e-7df3-42d4-81db-3d0cddb7f67a · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Secukinumab studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
Claims that go past the evidence
Things said about this substance that sound reasonable, and the exact step that is missing between the evidence and the claim.
✗Goes past the evidence
That an inflammatory cytokine is pathogenic wherever it appears; IL-17A is protective in the intestinal barrier
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That cross-trial PASI 100 comparisons establish superiority of one IL-17 or IL-23 agent over another
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Every line above can be traced to the study named beside it. Follow the link and read it.
ERASURE and FIXTURE: PASI 75 in 77-82% at 12 weeks, and superiority over etanercept
In plain words
Two trials in 738 and 1,306 people with moderate-to-severe psoriasis. At the higher dose, roughly four in five reached a 75% improvement, against fewer than one in twenty on placebo and fewer than half on the older anti-TNF comparator.
What was measured
PASI 75 at week 12: 81.6% (ERASURE 300 mg) and 77.1% versus 44.0% etanercept (FIXTURE)
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Two 52-week phase 3 trials with co-primary endpoints of PASI 75 and modified IGA 0 or 1 at week 12. ERASURE: PASI 75 in 81.6% at 300 mg, 71.6% at 150 mg, 4.5% placebo. FIXTURE: 77.1% at 300 mg, 67.0% at 150 mg, 44.0% for etanercept 50 mg twice weekly and 4.9% placebo. The active-comparator arm is what makes FIXTURE unusually informative: it is a direct measurement against the previous standard rather than against nothing.
Written into the record, not signed off as a reviewed claim
Crohn disease: blocking IL-17A made the disease worse
In plain words
A proof-of-concept trial in 59 people with active Crohn disease found secukinumab was not merely ineffective but associated with more adverse events and more discontinuation for lack of effect than placebo.
What was measured
Primary endpoint not met; more adverse events and more withdrawals for lack of effect than placebo
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
Double-blind randomised placebo-controlled proof-of-concept study, 39 to secukinumab 2 x 10 mg/kg intravenously and 20 to placebo, mean baseline CDAI 307 and 301. Blockade of IL-17A was ineffective. Discontinuation for insufficient therapeutic effect occurred in 21% on secukinumab versus 10% on placebo, and 20 infections including four local fungal infections were seen on secukinumab against none on placebo. The paper is titled "unexpected results" and the finding is now the basis of a class contraindication.
Written into the record, not signed off as a reviewed claim
IL-17 turned out to be protective in the gut and pathogenic in the skin
In plain words
The same cytokine drives disease in one organ and defends another. The Crohn result forced the field to abandon the idea that an inflammatory cytokine is simply bad wherever it appears.
What was measured
Not recorded
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
IL-17A maintains intestinal epithelial tight junction integrity and antimicrobial peptide production, so neutralising it in a barrier already compromised by Crohn disease permits increased bacterial translocation. Every IL-17-directed agent now carries a warning about inflammatory bowel disease, and new-onset or exacerbated IBD has been reported on secukinumab. Upstream IL-23 blockade does not share this liability, which is a mechanistically informative dissociation.
Source
Hueber et al., Gut 2012, and the resulting class warning in the COSENTYX label
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
verified
Review state
Written into the record, not signed off as a reviewed claim
Candidiasis is a predictable consequence, not an idiosyncratic side effect
In plain words
IL-17A is the main defence of mouth, throat and skin against Candida. Blocking it produces thrush at a measurably higher rate than placebo, which is exactly what the biology predicts.
What was measured
Not recorded
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Mucocutaneous candidiasis occurred more frequently on secukinumab than placebo across the trial programme. People with inherited defects in IL-17 signalling, such as autosomal dominant hyper-IgE syndrome or IL-17F mutations, develop chronic mucocutaneous candidiasis, which is the natural experiment that predicted this. Most cases are mild and treatable without stopping the antibody.
Source
COSENTYX US Prescribing Information, Warnings and Precautions and Adverse Reactions
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
verified
Review state
Written into the record, not signed off as a reviewed claim
Clearance rate is read as the whole of the benefit
In plain words
PASI 75 and PASI 90 measure how much plaque is left. They do not measure how long remission lasts after stopping, nor whether joint damage is prevented, and marketing comparisons across the class rarely make that distinction.
What was measured
That higher skin clearance rates across separate trials establish superiority of one biologic over another
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
ERASURE and FIXTURE measured skin severity indices at week 12 with 52-week extension. Neither was designed to measure structural joint outcomes, drug-free remission or long-term cardiovascular risk in a population with known excess cardiovascular mortality. Cross-class comparisons of PASI 100 rates from separate trials are indirect and subject to differing baseline severity and washout requirements.
Source
Endpoint structure of ERASURE and FIXTURE
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
caution
Review state
Written into the record, not signed off as a reviewed claim
Where else this substance is registered
FDA substance identifier (UNII)
DLG4EML025
RxNorm concept
1599788
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
2 approved applications cover products containing this substance. The earliest was BLA125504, approved 20150121 to NOVARTIS PHARMS CORP.
This order is fixed in code and does not count clicks or time on the page.
What is not here
3 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
The older medicine-wide conclusion held in this record
Written for a clinical reader, and about the medicine as a whole rather than about one indication, population and set of trials. RNAWiki does not treat it as a programme conclusion and no reviewer has signed it off in that form. It is here word for word because it is what the record holds.
A fully human antibody that neutralises interleukin-17A and cleared 75% of psoriasis in 81.6% of patients at 12 weeks against 4.5% on placebo, while making Crohn disease measurably worse in a proof-of-concept trial.
Recorded evidence blocks (13)
Q2
What did Secukinumab's largest trial (17743 people) and its longest (12 years) measure?
17743 people in Secukinumab's largest registered study, 12 years in its longest registered window, measuring Pharmacokinetics (PK) of AIN457: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part 1 Participants. ClinicalTrials.gov · 2026-09-01
86 phase3, 46 phase2, 34 phase4, 29 na or unstated, 18 phase1, 2 early phase1, 1 na; NCT03496831; 2017-12-31; no ageing endpoint recorded. Last human test completed 2026, NCT04179175.
Interpretation These counts include studies where Secukinumab was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase3
86
phase2
46
phase4
34
na or unstated
29
phase1
18
early phase1
2
2 more recorded rows
na
1
Last recorded human testNCT04179175
2026-07-15
recorded 2026-09-01 · last checked 2026-09-04
Q3
From rat to human: where has Secukinumab shown biomarker?
Pharmacokinetics (PK) of AIN457: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part 1 Participants — the recorded outcome words.
Show the evidence
rat
mechanism-only
humanNCT00669942
biomarker; Pharmacokinetics (PK) of AIN457: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part 1 Participants; 210
"The study was terminated prematurely after futility criterion was met at planned interim analysis of 41 patients."; 23 of 210 registered studies
Show the evidence
Trial
NCT00584740
terminated; "The study was terminated prematurely after futility criterion was met at planned interim analysis of 41 patients."
NCT01032915
terminated; "Results of a planned interim analysis did not show significant effects for any of the 3 AIN dose regimens versus placebo on any primary or secondary endpoint"
NCT01093846
terminated; "Core Study in Behcet's disease with mostly active uveitis did not meet its primary endpoint"
NCT01095250
terminated; "Terminated: Study in Behcet's disease with mostly active uveitis did not meet its primary endpoint."
NCT01103024
withdrawn; "Core study in non-infectious active uveitis was terminated"
NCT01327664
withdrawn; "Study will not be initiated as planned."
14 further recorded trials
NCT01364389
terminated; "Data did not show that the two biologic treatments impacted PMR disease activity to the same degree as steroid treatment within a 2-week treatment period."
NCT01478360
terminated; "Further investigations would require changes in study design; the use of different endpoints, a different IL-17 antibody or a different patient population."
NCT01874340
terminated; "Study terminated early based upon development of another anti-IL17 fully human monoclonal antibody with better potential for treating MS patients"
NCT02044848
terminated; "This study was terminated prematurely by the Sponsor for business reasons only."
NCT02599129
terminated; "low enrollment"
NCT03791060
terminated; "Study halted prematurely due COVID-19 pandemic and did not resume; participants are no longer being examined or receiving intervention."
NCT03866317
withdrawn; "Difficulty recruiting participants"
NCT04181762
terminated; "Study terminated by sponsor due to futility analysis"
NCT04237116
terminated; "Low enrollment"
NCT04274166
withdrawn; "Contracting never completed, closed the IRB"
NCT04488185
withdrawn; "low recruitment"
NCT04737330
terminated; "Analysis of blinded patient data showed a very low probability of the study meeting the primary efficacy endpoints. No safety concerns were identified"
NCT05206591
withdrawn; "Trial terminated due to strategic decision of senior management"
NCT05232864
terminated; "Study terminated by sponsor based on a futility analysis of the core study CAIN457Q12301"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Secukinumab used Secukinumab 10 mg/kg — over how long?
20 recorded entries; human; also "Secukinumab 10 mg/kg", "Secukinumab (75 mg)", "Secukinumab (150 mg)"
Show the evidence
human
NCT01250171
Secukinumab 10 mg/kg
NCT01358175
Secukinumab (75 mg)
NCT01358175
Secukinumab (150 mg)
NCT01365455
secukinumab 150 mg
NCT01365455
placebo to secukinumab 150 mg
NCT01406938
AIN457 150mg
14 more recorded rows
humanNCT01406938
AIN457 300mg
humanNCT01412944
secukinumab 150mg
humanNCT01412944
secukinumab 10mg/kg i.v. regimen
humanNCT01555125
secukinumab 300 mg
humanNCT01636687
Secukinumab 150mg
humanNCT01636687
Secukinumab 300mg
humanNCT01640951
AIN457 150 mg
humanNCT01640951
Secukinumab 150 mg
humanNCT01640951
AIN457 300 mg
humanNCT01640951
Secukinumab 300 mg
humanNCT01649375
AIN457 75 mg
humanNCT02159053
Secukinumab (AIN457) 150 mg s.c.
humanNCT03350815
150 mg open-label secukinumab
humanNCT03350815
150 mg double-blinded secukinumab
recorded 2026-09-01 · last checked 2026-09-04
Q6
Secukinumab's half-life is 22 to 31 days — which schedules were studied?
22 to 31 days, the half-life Secukinumab's label states. openfda-label · 77c4b13e-7df3-42d4-81db-3d0cddb7f67a · 2026-08-28
bioavailability 55% to 77% %.
Show the evidence
half life
22 to 31 days; The mean systemic clearance (CL) ranged from 0.14 L/day to 0.22 L/day and the mean half-life ranged from 22 to 31 days in PsO subjects following intravenous and subcutaneous administration across all PsO trials.
bioavailability
55% to 77% %; In healthy subjects and subjects with PsO, secukinumab bioavailability ranged from 55% to 77% following subcutaneous COSENTYX dose of 150 mg or 300 mg (administered as two injections of 150 mg).
metabolism
Elimination Metabolism The metabolic pathway of secukinumab has not been characterized.
recorded 2026-08-28 · last checked 2026-09-04
Q7
Which of a pasi 90 at week 52, a psoriasis area and severity index 100 response at week 16 and achieving an american college of rheumatology response 20 did Secukinumab's trials measure?
a pasi 90 at week 52, a psoriasis area and severity index 100 response at week 16 and achieving an american college of rheumatology response 20 lead 40 outcome terms across Secukinumab's trials. ClinicalTrials.gov · 2026-09-01
reported adverse events, adverse events serious adverse events and deaths, adverse events and serious adverse events, adverse events as a measure of safety and tolerability, achieving an american college of rheumatology response 20 and polymyalgia rheumatica activity follow.
Show the evidence
total neutrophil cell count in 106/ in induced sputum
1
adverse events
1
rate of recurrence
1
reported adverse events
1
adverse events serious adverse events and deaths
1
adverse events and serious adverse events
1
14 more recorded rows
adverse events as a measure of safety and tolerability
1
achieving an american college of rheumatology response 20
1
polymyalgia rheumatica activity
1
adverse events as a measure of safety
1
american college of rheumatology 20 response
1
auc0 12
1
auclast
1
aucinf
1
physician s global assessment
1
incidence of treatment emergent adverse events
1
iga mod 2011 0 or 1 at week 12
1
papule/pustule count at week 16
1
hidradenitis suppurativa clinical response
1
gene expression
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Secukinumab's 27 ongoing trials reports first?
Proportion of secukinumab treated PsO participants free of relapse after secukinumab withdrawal; Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 24; latest 2031-03-11
Show the evidence
Trial
NCT04239859
"Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis"; n 40; "Proportion of secukinumab treated PsO participants free of relapse after secukinumab withdrawal"; 2027-12
NCT05303285
"A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis"; n 100; "Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 24"; 2026-08-31
NCT05583604
"Managed Access Programs for AIN457, Secukinumab"
NCT05622708
"A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission"; n 240; "The proportion of participants remaining flare-free during Treatment Period 2"; 2028-04-04
NCT05921994
"Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa."; n 436; "Proportion of patients receiving up-titration"; 2027-03-31
NCT06142357
"Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis"; n 199; "Drug survival rate of secukinumab"; 2027-08-31
14 further recorded trials
NCT06331312
"Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)"; n 162; "Incidences of treatment emergent adverse events (AEs) and serious adverse events (SAEs)"; 2028-05-08
NCT06398106
"Proactive TDM Versus Standard Use of Biologics in Psoriasis"; n 210; "Non-inferiority of sustained disease control"; 2028-03-01
NCT06444087
"Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation"; n 192; "Proportion of patients achieving at least 30% reduction of the NRS score for at least one the assessed symptoms"; 2027-06-30
NCT06517732
"Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation"; n 107; "Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)"; 2026-12-31
NCT06751238
"Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA)."; n 20; "Maximum concentration on Day 1"; 2031-03-11
NCT06785675
"Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab."; n 53; "The absolute scores of each of the 4 domains of the Treatment Satisfaction Questionnaire for Medication (TSQM) questionnaire"; 2026-10-10
NCT06785779
"Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia"; n 77; "Mean Score in the Treatment Satisfaction Questionnaire (TSQM)"; 2026-09-30
NCT06786936
"Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms"; n 50; "Changes in glutamate concentration in the NAcc as measured by 7T MRS."; 2027-04-30
NCT06833112
"Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis"; n 10; "Assessment of SpondyloArthritis International Society 40 (ASAS 40)"; 2028-02
NCT06905288
"Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea."; n 70; "Change from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)"; 2026-12-31
NCT06945107
"A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy"; n 308; "The percentage of participants achieving static Physician's Global Assessment (sPGA) score of clear (0) or almost clear (1)"; 2027-01-19
NCT07109765
"Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa"; n 50; "Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)"; 2026-06-01
NCT07138898
"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty"; n 80; "Incidence of wound complications"; 2028-01
NCT07190053
"Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry."; n 100; "Number of patients who had the following long-term treatment strategy after achieving inactive disease on secukinumab"; 2029-09-18
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which running trial of Secukinumab could settle lifespan?
NCT06142357 measures Drug survival rate of secukinumab, reading out 2027-08-31.
1 open trial; n 199; "Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis"
Show the evidence
TrialNCT06142357
"Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis"; n 199; "Drug survival rate of secukinumab"; 2027-08-31
Q10
Which 31 trials of Secukinumab posted no result?
Posted no result
31 of 31 completed trials
Registrations
NCT01539213, NCT01828086, NCT02607774, NCT03358134, NCT03496831 and NCT02483234, and 25 more
Completion dates
oldest 2013-01; newest 2024-05-28
Show the evidence
Trial
NCT01539213
2013-01
NCT01828086
2015-10
NCT02607774
2016-12-20
NCT03358134
2017-10
NCT03496831
2017-12-31
NCT02483234
2018-09-30
14 further recorded trials
NCT03099980
2019-01
NCT05676333
2019-02-22
NCT03828643
2019-04-12
NCT03149900
2019-07-25
NCT02854163
2019-09-18
NCT02733094
2019-09-19
NCT03568136
2020-05-04
NCT05320159
2021-03-31
NCT04589026
2021-05-06
NCT05368818
2021-05-06
NCT03955861
2021-07-17
NCT05344482
2021-08-31
NCT05513014
2021-08-31
NCT05650060
2021-12-23
Q11
At the median, Secukinumab's trials enrolled 102 people — anything larger?
Median enrolment
102
Largest enrolment
17743
Registered trials counted
209
Q12
What do 16345 spontaneous reports say about Secukinumab — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Secukinumab appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 16345 reaction mentions were counted: psoriasis 3770; pain 2393; arthralgia 2101; psoriatic arthropathy 1516. open-targets-adr · CHEMBL1743068 · 2026-06-24
Show the evidence
psoriasis
3770
pain
2393
arthralgia
2101
psoriatic arthropathy
1516
malaise
1487
pruritus
1411
4 more recorded rows
pain in extremity
1171
nasopharyngitis
997
musculoskeletal stiffness
765
joint swelling
734
recorded 2026-06-24 · last checked 2026-09-04
Q13
Secukinumab and CYP3A4: shared by which compounds?
CYP3A4 appear in Secukinumab's recorded interaction sentences, 1 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
CYP3A4pharmacokinetics
Drug Interactions Cytochrome P450 Substrates In adult subjects with PsO, midazolam (CYP3A4 substrate) PK was similar when administered alone, or when administered following either a single or five weekly subcutaneous administrations of 300 mg of COSENTYX [see Drug Interactions (7)] .
recorded 2026-08-30 · last checked 2026-09-04
Q14
What is recorded about Secukinumab and autophagy?
"Here, it could be observed that compared with serum-free condition, the combination of secukinumab and serum-free status better promoted autophagy (observed by LC3 conversion rate, p62 protein expression and the formation of autophagosomes), and more significantly inhibited the survival and function (observed by Trypan blue staining,…" — where Secukinumab and autophagy appear together. Europe PMC · pathway abstract search · 2023-05-17
autophagy; PMID 37195553
Show the evidence
autophagy
PMID 37195553
"Here, it could be observed that compared with serum-free condition, the combination of secukinumab and serum-free status better promoted autophagy (observed by LC3 conversion rate, p62 protein expression and the formation of autophagosomes), and more significantly inhibited the survival and function (observed by Trypan blue staining, CCK-8, Transwell, and scratch assays) in HCC HepG2 cells."
PMID 37195553
"Nude mice experiments demonstrated that compared to the lenvatinib-alone group, the combination group of lenvatinib and secukinumab better inhibited the in vivo tumorigenesis of HepG2 cells and enhanced autophagy in xenotumor tissues."
PMID 37195553
"In conclusion, the antagonism of IL-17A with secukinumab, due to the upregulation on BCL2-related autophagic cell death, can cooperate with starvation therapy in inhibiting HCC carcinogenesis."
recorded 2023-05-17 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 10 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.